Ascendis Pharma A/S (ASND)
After hours:
| Previous Close | 122.85 |
| Open | 123.10 |
| Bid | 131.03 x 100 |
| Ask | 131.32 x 100 |
| Day's Range | 122.73 - 133.09 |
| 52 Week Range | 83.75 - 161.00 |
| Volume | |
| Avg. Volume | 375,208 |
| Market Cap | 7.49B |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Zacks
FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing
Per the FDA, the data submitted by Ascendis (ASND) for its hormone replacement therapy constitutes a major amendment to its previously-submitted data. A final decision is expected by Aug 14.
- Reuters
UPDATE 2-US FDA extends review of Ascendis Pharma's hormone disorder therapy
The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's therapy to treat adult patients with a hormone disorder by three months, the company said on Tuesday. U.S.-listed shares of the company were down 6.6% in late afternoon trading. The health regulator notified that data submitted for the ongoing review of the therapy, called TransCon PTH, constituted "a major amendment" to the company's application seeking market approval.
- Insider Monkey
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript May 4, 2024 Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and welcome to the Q1 2024 Ascendis Pharma Earnings Conference Call. At this time, all […]
